MiNK Therapeutics (INKT) Stock Price, News & Analysis

Company Overview

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Key Stats

• Today's Range: $8.80 to $9.23
• 50-Day Range: $5.51 to $12.03
• 52-Week Range: $4.56 to $19.00
• Volume: 7,031 shs
• Average Volume: 15,812 shs
• Market Capitalization: $36.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.50
• Consensus Rating: Buy

MiNK Therapeutics Stock Analysis - MarketRank™

MiNK Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 601st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MiNK Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MiNK Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MiNK Therapeutics are expected to grow in the coming year, from ($2.75) to ($2.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MiNK Therapeutics is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MiNK Therapeutics is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.92% of the float of MiNK Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

MiNK Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MiNK Therapeutics has recently increased by 8.96%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MiNK Therapeutics does not currently pay a dividend.

Dividend Growth

MiNK Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.92% of the float of MiNK Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

MiNK Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MiNK Therapeutics has recently increased by 8.96%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.45

News Sentiment

MiNK Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for MiNK Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for INKT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MiNK Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.60% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.87% of the stock of MiNK Therapeutics is held by institutions.

INKT Stock Analysis - Frequently Asked Questions

How have INKT shares performed this year?

MiNK Therapeutics' stock was trading at $6.9690 at the beginning of the year. Since then, INKT shares have increased by 31.8% and is now trading at $9.1850.
View the best growth stocks for 2025 here.

How were MiNK Therapeutics' earnings last quarter?

MiNK Therapeutics, Inc. (NASDAQ:INKT) posted its quarterly earnings results on Tuesday, March, 18th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.12.

When did MiNK Therapeutics' stock split?

Shares of MiNK Therapeutics reverse split on Tuesday, January 28th 2025. The 1-10 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did MiNK Therapeutics IPO?

MiNK Therapeutics (INKT) raised $43 million in an initial public offering on Friday, October 15th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share.

Who are MiNK Therapeutics' major shareholders?

MiNK Therapeutics' top institutional shareholders include Renaissance Technologies LLC (2.57%), Geode Capital Management LLC (2.43%) and HighTower Advisors LLC (1.28%). Insiders that own company stock include Agenus Inc and Ulf Wiinberg.
View institutional ownership trends.

How do I buy shares of MiNK Therapeutics?

Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MiNK Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MiNK Therapeutics investors own include Agenus (AGEN), HubSpot (HUBS), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Bank of America (BAC).

Company Calendar

• Last Earnings: 3/18/2025
• Today: 3/27/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INKT
• CIK: 1840229
• Web: www.minktherapeutics.com
• Phone: 212-994-8250
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $37.50
• High Stock Price Target: $40.00
• Low Stock Price Target: $35.00
• Potential Upside/Downside: +308.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-22,460,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -189.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.89
• Quick Ratio: 0.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.23) per share
• Price / Book: -1.76

Miscellaneous

• Outstanding Shares: 3,966,000
• Free Float: 3,147,000
• Market Cap: $36.43 million
• Optionable: No Data
• Beta: 0.16